Sol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Conference

Rhea-AI Summary

Sol-Gel Technologies (NASDAQ: SLGL), a clinical-stage dermatology firm, announced its participation in two upcoming virtual investor conferences. Dr. Alon Seri-Levy, CEO, will present at the Solebury Trout 2021 Virtual Investor Conference from January 11-15, 2020, with on-demand access available. Additionally, CFO Gilad Mamlok will speak at the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2020, accessible to participants. Sol-Gel is focused on developing topical drugs for skin diseases, including treatments for acne and rosacea.

NESS ZIONA, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present an overview of the Company and provide a business update at the following virtual investor conferences.

Solebury Trout 2021 Virtual Investor Conference
Speaker:		Dr. Alon Seri-Levy, Chief Executive Officer
Date:		January 11-15, 2020
Access:		Available on demand at the following Link
H.C. Wainwright BioConnect 2021 Virtual Conference
Speakers:		Gilad Mamlok, Chief Financial Officer
Date:		January 11-14, 2020
Access:		Available on demand to conference participants.

About Sol-Gel Technologies

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo (benzoyl peroxide and tretinoin) cream, under investigation for the treatment of acne vulgaris, and Epsolay®, under investigation for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.

For further information, please contact:

Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433

Investor Contact:
Michael Levitan
Solebury Trout
+1-646-378-2920
mlevitan@soleburytrout.com

Source: Sol-Gel Technologies Ltd.

FAQ

What is Sol-Gel Technologies' focus area?

Sol-Gel Technologies specializes in developing and commercializing branded and generic topical drug products for skin diseases.

Who will represent Sol-Gel at the Solebury Trout 2021 Virtual Investor Conference?

Dr. Alon Seri-Levy, the CEO, will represent Sol-Gel Technologies at the conference.

When is the Solebury Trout 2021 Virtual Investor Conference?

The conference will take place from January 11-15, 2020.

How can I access Sol-Gel's presentation at the Solebury Trout conference?

The presentation will be available on demand through a provided link.

Who will speak for Sol-Gel at the H.C. Wainwright BioConnect 2021 Virtual Conference?

Gilad Mamlok, the CFO, will represent Sol-Gel Technologies.

What are the dates for the H.C. Wainwright BioConnect 2021 Virtual Conference?

The conference is scheduled from January 11-14, 2020.